A Phase 4 interventional study of Maraviroc and Maraviroc in Healthy, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-25.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.
Drug interaction study
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc
Drug: Maraviroc · Drug: Raltegravir
Drug: Raltegravir
300 milligrams(mg) every 12 hours Days 6-11
Also known as: Selzentry, Celsentri
Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of AUCτ of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir).
Time frame: Days 11 and 14
Maraviroc Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax)
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of Cmax of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir). Cmax is the maximum plasma concentration.
Time frame: Days 11 and 14
Raltegravir Pharmacokinetics (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of AUCτ of raltegravir co-administered with maraviroc (Test) versus raltegravir administered alone (Reference)). Pharmacokinetics were assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir).
Time frame: Days 3 and 14
Raltegravir Pharmacokinetics (PK) Parameter: Maximum Concentration (Cmax)
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of Cmax of raltegravir co-administered with maraviroc (Test) versus raltegravir administered alone (Reference)). Pharmacokinetics assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir). Cmax is the maximum plasma concentration.
Time frame: Days 3 and 14
Maraviroc Pharmacokinetic (PK) Parameter: 12-Hour Trough Concentration (C12)
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of C12 of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir). C12 is the 12-hour trough concentration.
Time frame: Days 11 and 14
Raltegravir Pharmacokinetics (PK) Parameter: 12-Hour Trough Concentration (C12)
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of C12 of raltegravir co-administered with maraviroc (Test) vs. raltegravir administered alone (Reference)). Pharmacokinetics were assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir). C12 is the 12-hour trough concentration.
Time frame: Days 3 and 14
One site in the United States
| Milestone | Maraviroc / Raltegravir (Alone and Co-administered) |
|---|---|
| Started | 18 |
| Raltegravir alone (days 1 - 3) | 18 |
| Washout (days 4 - 5) | 18 |
| Maraviroc alone (days 6 - 11) | 18 |
| Raltegravir + maraviroc (days 12 - 14) | 17 |
| Completed | 17 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of AUCτ of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir).
| ng.hr/mL | Maraviroc + Raltegravir (Test) | Maraviroc (Reference) |
|---|---|---|
| Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) | 2551.9 ± 786.68 | 2971.6 ± 841.65 |
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of Cmax of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir). Cmax is the maximum plasma concentration.
| ng/mL | Maraviroc + Raltegravir (Test) | Maraviroc (Reference) |
|---|---|---|
| Maraviroc Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax) | 691.6 ± 322.24 | 851.4 ± 349.38 |
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of AUCτ of raltegravir co-administered with maraviroc (Test) versus raltegravir administered alone (Reference)). Pharmacokinetics were assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir).
| ng.hr/mL | Maraviroc + Raltegravir (Test) | Raltegravir (Reference) |
|---|---|---|
| Raltegravir Pharmacokinetics (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) | 6287.5 ± 3979.30 | 9122.4 ± 5311.34 |
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of C12 of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir). C12 is the 12-hour trough concentration.
| ng/mL | Maraviroc + Raltegravir (Test) | Maraviroc (Reference) |
|---|---|---|
| Maraviroc Pharmacokinetic (PK) Parameter: 12-Hour Trough Concentration (C12) | 48.34 ± 13.70 | 53.36 ± 14.03 |
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of Cmax of raltegravir co-administered with maraviroc (Test) versus raltegravir administered alone (Reference)). Pharmacokinetics assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir). Cmax is the maximum plasma concentration.
| ng/mL | Maraviroc + Raltegravir (Test) | Raltegravir (Reference) |
|---|---|---|
| Raltegravir Pharmacokinetics (PK) Parameter: Maximum Concentration (Cmax) | 2169.6 ± 1570.58 | 3026.6 ± 2030.15 |
Effect of maraviroc on pharmacokinetics of raltegravir (comparison of C12 of raltegravir co-administered with maraviroc (Test) vs. raltegravir administered alone (Reference)). Pharmacokinetics were assessed on Day 3 (raltegravir) and Day 14 (maraviroc and raltegravir). C12 is the 12-hour trough concentration.
| ng/mL | Maraviroc + Raltegravir (Test) | Raltegravir (Reference) |
|---|---|---|
| Raltegravir Pharmacokinetics (PK) Parameter: 12-Hour Trough Concentration (C12) | 51.16 ± 22.64 | 73.69 ± 36.21 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc | — | 0/18 (0%) | — |
| Maraviroc + Raltegravir | — | 0/17 (0%) | — |
| Raltegravir | — | 0/18 (0%) | — |
| Event | Maraviroc | Maraviroc + Raltegravir | Raltegravir |
|---|---|---|---|
| HeadacheNervous system disorders | 0/18 | 1/17 | 2/18 |
| DyspepsiaGastrointestinal disorders | 0/18 | 1/17 | 0/18 |
| Back painMusculoskeletal and connective tissue disorders | 0/18 | 1/17 | 0/18 |
| Peripheral neurophathyNervous system disorders | 1/18 | 1/17 | 1/18 |
| SomnolenceNervous system disorders | 1/18 | 1/17 | 0/18 |
| ConstipationGastrointestinal disorders | 1/18 | 0/17 | 0/18 |
| FolliculitisInfections and infestations | 1/18 | 0/17 | 1/18 |
| Age Continuous(years) | Maraviroc / Raltegravir (Alone and Co-administered) |
|---|---|
| Mean | 36.3 ± 9.1 |
| Sex: Female, Male(Participants) | Maraviroc / Raltegravir (Alone and Co-administered) |
|---|---|
| Female | 2 |
| Male | 16 |
The record gives a start of Feb 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Maraviroc · Raltegravir